UBS Maintains Buy on United Therapeutics, Lowers Price Target to $385

Benzinga · 06/30 17:00
UBS analyst Ashwani Verma maintains United Therapeutics (NASDAQ:UTHR) with a Buy and lowers the price target from $410 to $385.